SCOPUS 정보 검색 플랫폼

Volumn 91, Issue 7, 2012, Pages 1023-1030

A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma

(10) Ahn, Jae Sook a Yang, Deok Hwan a Jung, Sung Hoon a Park, Hyung Chul a Moon, Joon Ho b Sohn, Sang Kyun b Bae, Soo Young a Kim, Yeo Kyeoung a Kim, Hyeoung Joon a Lee, Je Jung a

a Chonnam National University (South Korea)

b Kyungpook National University Hospital (South Korea)

Author keywords

Bortezomib; Multiple myeloma; Refractory; Relapse; Thalidomide

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; THALIDOMIDE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES ZOSTER; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SENSORY NEUROPATHY; SURVIVAL RATE; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THALIDOMIDE;

EID: 84862769560 PISSN: 09395555 EISSN: 14320584 Source Type: Journal
DOI: 10.1007/s00277-012-1420-7 Document Type: Article

Times cited : (13)

References (31)

1
- 77955171366
- Multiple myeloma in Korea: Past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party
- 20544403 10.1007/s12185-010-0617-6
- JH Lee DS Lee JJ Lee YH Chang JY Jin DY Jo SM Bang HJ Kim JS Kim K Kim HS Eom CK Min SS Yoon SH Kim C Suh KS Cho 2010 Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party Int J Hematol 92 52 57 20544403 10.1007/s12185-010-0617-6
- (2010) Int J Hematol , vol.92 , pp. 52-57
- Lee, J.H.¹ Lee, D.S.² Lee, J.J.³ Chang, Y.H.⁴ Jin, J.Y.⁵ Jo, D.Y.⁶ Bang, S.M.⁷ Kim, H.J.⁸ Kim, J.S.⁹ Kim, K.¹⁰ Eom, H.S.¹¹ Min, C.K.¹² Yoon, S.S.¹³ Kim, S.H.¹⁴ Suh, C.¹⁵ Cho, K.S.¹⁶

2
- 41949130070
- Improved survival in multiple myeloma and the impact of novel therapies
- 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
- SK Kumar SV Rajkumar A Dispenzieri MQ Lacy SR Hayman FK Buadi SR Zeldenrust D Dingli SJ Russell JA Lust PR Greipp RA Kyle MA Gertz 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 17975015 10.1182/blood-2007-10-116129 1:CAS:528:DC%2BD1cXivFaktrk%3D
- (2008) Blood , vol.111 , pp. 2516-2520
- Kumar, S.K.¹ Rajkumar, S.V.² Dispenzieri, A.³ Lacy, M.Q.⁴ Hayman, S.R.⁵ Buadi, F.K.⁶ Zeldenrust, S.R.⁷ Dingli, D.⁸ Russell, S.J.⁹ Lust, J.A.¹⁰ Greipp, P.R.¹¹ Kyle, R.A.¹² Gertz, M.A.¹³

3
- 20444433230
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
- 15958804 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D
- PG Richardson P Sonneveld MW Schuster D Irwin EA Stadtmauer T Facon JL Harousseau D Ben-Yehuda S Lonial H Goldschmidt D Reece JF San-Miguel J Blade M Boccadoro J Cavenagh WS Dalton AL Boral DL Esseltine JB Porter D Schenkein KC Anderson 2005 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2487 2498 15958804 10.1056/NEJMoa043445 1:CAS:528:DC%2BD2MXltlaksLc%3D
- (2005) N Engl J Med , vol.352 , pp. 2487-2498
- Richardson, P.G.¹ Sonneveld, P.² Schuster, M.W.³ Irwin, D.⁴ Stadtmauer, E.A.⁵ Facon, T.⁶ Harousseau, J.L.⁷ Ben-Yehuda, D.⁸ Lonial, S.⁹ Goldschmidt, H.¹⁰ Reece, D.¹¹ San-Miguel, J.F.¹² Blade, J.¹³ Boccadoro, M.¹⁴ Cavenagh, J.¹⁵ Dalton, W.S.¹⁶ Boral, A.L.¹⁷ Esseltine, D.L.¹⁸ Porter, J.B.¹⁹ Schenkein, D.²⁰ Anderson, K.C.²¹ more..

4
- 35148825003
- Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
- 17690257 10.1182/blood-2006-08-036947 1:CAS:528:DC%2BD2sXhtlarur3K
- PG Richardson P Sonneveld M Schuster D Irwin E Stadtmauer T Facon JL Harousseau D Ben-Yehuda S Lonial H Goldschmidt D Reece JS Miguel J Blade M Boccadoro J Cavenagh M Alsina SV Rajkumar M Lacy A Jakubowiak W Dalton A Boral DL Esseltine D Schenkein KC Anderson 2007 Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial Blood 110 3557 3560 17690257 10.1182/blood-2006-08-036947 1:CAS:528: DC%2BD2sXhtlarur3K
- (2007) Blood , vol.110 , pp. 3557-3560
- Richardson, P.G.¹ Sonneveld, P.² Schuster, M.³ Irwin, D.⁴ Stadtmauer, E.⁵ Facon, T.⁶ Harousseau, J.L.⁷ Ben-Yehuda, D.⁸ Lonial, S.⁹ Goldschmidt, H.¹⁰ Reece, D.¹¹ Miguel, J.S.¹² Blade, J.¹³ Boccadoro, M.¹⁴ Cavenagh, J.¹⁵ Alsina, M.¹⁶ Rajkumar, S.V.¹⁷ Lacy, M.¹⁸ Jakubowiak, A.¹⁹ Dalton, W.²⁰ more..

5
- 33644844108
- Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: Final time-to-event results from the SUMMIT trial
- 16470606 10.1002/cncr.21740 1:CAS:528:DC%2BD28XjtVCrsLc%3D
- PG Richardson B Barlogie J Berenson S Singhal S Jagannath DH Irwin SV Rajkumar G Srkalovic M Alsina KC Anderson 2006 Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial Cancer 106 1316 1319 16470606 10.1002/cncr.21740 1:CAS:528:DC%2BD28XjtVCrsLc%3D
- (2006) Cancer , vol.106 , pp. 1316-1319
- Richardson, P.G.¹ Barlogie, B.² Berenson, J.³ Singhal, S.⁴ Jagannath, S.⁵ Irwin, D.H.⁶ Rajkumar, S.V.⁷ Srkalovic, G.⁸ Alsina, M.⁹ Anderson, K.C.¹⁰

6
- 5644250621
- A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
- 15461622 10.1111/j.1365-2141.2004.05188.x 1:CAS:528:DC%2BD2cXpvFait7g%3D
- S Jagannath B Barlogie J Berenson D Siegel D Irwin PG Richardson R Niesvizky R Alexanian SA Limentani M Alsina J Adams M Kauffman DL Esseltine DP Schenkein KC Anderson 2004 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Br J Haematol 127 165 172 15461622 10.1111/j.1365-2141.2004.05188.x 1:CAS:528:DC%2BD2cXpvFait7g%3D
- (2004) Br J Haematol , vol.127 , pp. 165-172
- Jagannath, S.¹ Barlogie, B.² Berenson, J.³ Siegel, D.⁴ Irwin, D.⁵ Richardson, P.G.⁶ Niesvizky, R.⁷ Alexanian, R.⁸ Limentani, S.A.⁹ Alsina, M.¹⁰ Adams, J.¹¹ Kauffman, M.¹² Esseltine, D.L.¹³ Schenkein, D.P.¹⁴ Anderson, K.C.¹⁵

7
- 33644834155
- Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
- 16519697 10.1111/j.1600-0609.2005.00610.x 1:CAS:528:DC%2BD28XkvVOkurw%3D
- A Palumbo I Avonto B Bruno MT Ambrosini S Bringhen F Cavallo P Falco M Boccadoro 2006 Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma Eur J Haematol 76 273 277 16519697 10.1111/j.1600-0609.2005.00610.x 1:CAS:528:DC%2BD28XkvVOkurw%3D
- (2006) Eur J Haematol , vol.76 , pp. 273-277
- Palumbo, A.¹ Avonto, I.² Bruno, B.³ Ambrosini, M.T.⁴ Bringhen, S.⁵ Cavallo, F.⁶ Falco, P.⁷ Boccadoro, M.⁸

8
- 21344459018
- Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma
- 15953002 10.1111/j.1365-2141.2005.05521.x 1:CAS:528:DC%2BD2MXms1ehsL4%3D
- C Kyriakou K Thomson S D'Sa A Flory J Hanslip AH Goldstone KL Yong 2005 Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma Br J Haematol 129 763 770 15953002 10.1111/j.1365-2141.2005.05521.x 1:CAS:528:DC%2BD2MXms1ehsL4%3D
- (2005) Br J Haematol , vol.129 , pp. 763-770
- Kyriakou, C.¹ Thomson, K.² D'Sa, S.³ Flory, A.⁴ Hanslip, J.⁵ Goldstone, A.H.⁶ Yong, K.L.⁷

9
- 0042161862
- Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma
- 12899716 10.1046/j.1365-2141.2003.04473.x 1:CAS:528:DC%2BD3sXnsVCgurs%3D
- MH Kropff N Lang G Bisping N Domine G Innig M Hentrich M Mitterer T Sudhoff R Fenk C Straka A Heinecke OM Koch H Ostermann WE Berdel J Kienast 2003 Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma Br J Haematol 122 607 616 12899716 10.1046/j.1365-2141.2003.04473.x 1:CAS:528:DC%2BD3sXnsVCgurs%3D
- (2003) Br J Haematol , vol.122 , pp. 607-616
- Kropff, M.H.¹ Lang, N.² Bisping, G.³ Domine, N.⁴ Innig, G.⁵ Hentrich, M.⁶ Mitterer, M.⁷ Sudhoff, T.⁸ Fenk, R.⁹ Straka, C.¹⁰ Heinecke, A.¹¹ Koch, O.M.¹² Ostermann, H.¹³ Berdel, W.E.¹⁴ Kienast, J.¹⁵

10
- 34548539381
- Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: Combination therapy improves time to progression
- 17679727 10.1200/JCO.2006.10.5460 1:CAS:528:DC%2BD2sXhtFanu73M
- RZ Orlowski A Nagler P Sonneveld J Blade R Hajek A Spencer J San Miguel T Robak A Dmoszynska N Horvath I Spicka HJ Sutherland AN Suvorov SH Zhuang T Parekh L Xiu Z Yuan W Rackoff JL Harousseau 2007 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression J Clin Oncol 25 3892 3901 17679727 10.1200/JCO.2006.10.5460 1:CAS:528:DC%2BD2sXhtFanu73M
- (2007) J Clin Oncol , vol.25 , pp. 3892-3901
- Orlowski, R.Z.¹ Nagler, A.² Sonneveld, P.³ Blade, J.⁴ Hajek, R.⁵ Spencer, A.⁶ San Miguel, J.⁷ Robak, T.⁸ Dmoszynska, A.⁹ Horvath, N.¹⁰ Spicka, I.¹¹ Sutherland, H.J.¹² Suvorov, A.N.¹³ Zhuang, S.H.¹⁴ Parekh, T.¹⁵ Xiu, L.¹⁶ Yuan, Z.¹⁷ Rackoff, W.¹⁸ Harousseau, J.L.¹⁹

11
- 34447114537
- Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma
- 17614819 10.1111/j.1365-2141.2007.06656.x 1:CAS:528:DC%2BD2sXpsVClt7g%3D
- M Kropff G Bisping E Schuck P Liebisch N Lang M Hentrich T Dechow N Kroger H Salwender B Metzner O Sezer M Engelhardt HH Wolf H Einsele S Volpert A Heinecke WE Berdel J Kienast 2007 Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma Br J Haematol 138 330 337 17614819 10.1111/j.1365-2141.2007.06656.x 1:CAS:528:DC%2BD2sXpsVClt7g%3D
- (2007) Br J Haematol , vol.138 , pp. 330-337
- Kropff, M.¹ Bisping, G.² Schuck, E.³ Liebisch, P.⁴ Lang, N.⁵ Hentrich, M.⁶ Dechow, T.⁷ Kroger, N.⁸ Salwender, H.⁹ Metzner, B.¹⁰ Sezer, O.¹¹ Engelhardt, M.¹² Wolf, H.H.¹³ Einsele, H.¹⁴ Volpert, S.¹⁵ Heinecke, A.¹⁶ Berdel, W.E.¹⁷ Kienast, J.¹⁸

12
- 33644916110
- Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
- 16418495 10.1200/JCO.2005.03.2383 1:CAS:528:DC%2BD28Xitl2qt70%3D
- JR Berenson HH Yang K Sadler SG Jarutirasarn RA Vescio R Mapes M Purner SP Lee J Wilson B Morrison J Adams D Schenkein R Swift 2006 Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma J Clin Oncol 24 937 944 16418495 10.1200/JCO.2005.03.2383 1:CAS:528:DC%2BD28Xitl2qt70%3D
- (2006) J Clin Oncol , vol.24 , pp. 937-944
- Berenson, J.R.¹ Yang, H.H.² Sadler, K.³ Jarutirasarn, S.G.⁴ Vescio, R.A.⁵ Mapes, R.⁶ Purner, M.⁷ Lee, S.P.⁸ Wilson, J.⁹ Morrison, B.¹⁰ Adams, J.¹¹ Schenkein, D.¹² Swift, R.¹³

13
- 33947575994
- Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
- 17148584 1:CAS:528:DC%2BD2sXjvVynsrg%3D
- A Palumbo MT Ambrosini G Benevolo P Pregno N Pescosta V Callea C Cangialosi T Caravita F Morabito P Musto S Bringhen P Falco I Avonto F Cavallo M Boccadoro 2007 Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma Blood 109 2767 2772 17148584 1:CAS:528:DC%2BD2sXjvVynsrg%3D
- (2007) Blood , vol.109 , pp. 2767-2772
- Palumbo, A.¹ Ambrosini, M.T.² Benevolo, G.³ Pregno, P.⁴ Pescosta, N.⁵ Callea, V.⁶ Cangialosi, C.⁷ Caravita, T.⁸ Morabito, F.⁹ Musto, P.¹⁰ Bringhen, S.¹¹ Falco, P.¹² Avonto, I.¹³ Cavallo, F.¹⁴ Boccadoro, M.¹⁵

14
- 54249122860
- Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma
- 18645194 10.1200/JCO.2007.14.2372 1:CAS:528:DC%2BD1cXhtlSqsb7J
- DE Reece GP Rodriguez C Chen S Trudel V Kukreti J Mikhael M Pantoja W Xu AK Stewart 2008 Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma J Clin Oncol 26 4777 4783 18645194 10.1200/JCO.2007.14.2372 1:CAS:528:DC%2BD1cXhtlSqsb7J
- (2008) J Clin Oncol , vol.26 , pp. 4777-4783
- Reece, D.E.¹ Rodriguez, G.P.² Chen, C.³ Trudel, S.⁴ Kukreti, V.⁵ Mikhael, J.⁶ Pantoja, M.⁷ Xu, W.⁸ Stewart, A.K.⁹

15
- 70349435626
- DSMM XI study: Dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
- 19274460 10.1007/s00277-009-0726-6 1:CAS:528:DC%2BD1MXhtFCju7rL
- M Kropff P Liebisch S Knop K Weisel H Wand CN Gann WE Berdel H Einsele 2009 DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma Ann Hematol 88 1125 1130 19274460 10.1007/s00277-009-0726-6 1:CAS:528:DC%2BD1MXhtFCju7rL
- (2009) Ann Hematol , vol.88 , pp. 1125-1130
- Kropff, M.¹ Liebisch, P.² Knop, S.³ Weisel, K.⁴ Wand, H.⁵ Gann, C.N.⁶ Berdel, W.E.⁷ Einsele, H.⁸

16
- 67650882695
- Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: High response rates in a phase II clinical trial
- 19225538 10.1038/leu.2009.26 1:CAS:528:DC%2BD1MXoslOhs7k%3D
- CB Reeder DE Reece V Kukreti C Chen S Trudel J Hentz B Noble NA Pirooz JE Spong JG Piza VH Zepeda JR Mikhael JF Leis PL Bergsagel R Fonseca AK Stewart 2009 Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial Leukemia 23 1337 1341 19225538 10.1038/leu.2009.26 1:CAS:528: DC%2BD1MXoslOhs7k%3D
- (2009) Leukemia , vol.23 , pp. 1337-1341
- Reeder, C.B.¹ Reece, D.E.² Kukreti, V.³ Chen, C.⁴ Trudel, S.⁵ Hentz, J.⁶ Noble, B.⁷ Pirooz, N.A.⁸ Spong, J.E.⁹ Piza, J.G.¹⁰ Zepeda, V.H.¹¹ Mikhael, J.R.¹² Leis, J.F.¹³ Bergsagel, P.L.¹⁴ Fonseca, R.¹⁵ Stewart, A.K.¹⁶

17
- 75149140434
- Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma
- 19919652 10.1111/j.1365-2141.2009.07981.x 1:CAS:528:DC%2BC3cXjsFeqt78%3D
- WI Bensinger S Jagannath R Vescio E Camacho J Wolf D Irwin G Capo M McKinley P Potts DH Vesole A Mazumder J Crowley P Becker J Hilger BG Durie 2010 Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma Br J Haematol 148 562 568 19919652 10.1111/j.1365-2141.2009.07981.x 1:CAS:528:DC%2BC3cXjsFeqt78%3D
- (2010) Br J Haematol , vol.148 , pp. 562-568
- Bensinger, W.I.¹ Jagannath, S.² Vescio, R.³ Camacho, E.⁴ Wolf, J.⁵ Irwin, D.⁶ Capo, G.⁷ McKinley, M.⁸ Potts, P.⁹ Vesole, D.H.¹⁰ Mazumder, A.¹¹ Crowley, J.¹² Becker, P.¹³ Hilger, J.¹⁴ Durie, B.G.¹⁵

18
- 34848815741
- The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone
- 17650451 10.3324/haematol.11228 1:CAS:528:DC%2BD2sXhtFKrs77J
- FE Davies P Wu M Jenner M Srikanth R Saso GJ Morgan 2007 The combination of cyclophosphamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone Haematologica 92 1149 1150 17650451 10.3324/haematol.11228 1:CAS:528: DC%2BD2sXhtFKrs77J
- (2007) Haematologica , vol.92 , pp. 1149-1150
- Davies, F.E.¹ Wu, P.² Jenner, M.³ Srikanth, M.⁴ Saso, R.⁵ Morgan, G.J.⁶

19
- 77950563131
- Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: A phase II study
- 19921192 10.1007/s00277-009-0856-x 1:CAS:528:DC%2BC3cXjtlagsrw%3D
- YK Kim SK Sohn JH Lee DH Yang JH Moon JS Ahn HJ Kim JJ Lee 2010 Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study Ann Hematol 89 475 482 19921192 10.1007/s00277-009-0856-x 1:CAS:528:DC%2BC3cXjtlagsrw%3D
- (2010) Ann Hematol , vol.89 , pp. 475-482
- Kim, Y.K.¹ Sohn, S.K.² Lee, J.H.³ Yang, D.H.⁴ Moon, J.H.⁵ Ahn, J.S.⁶ Kim, H.J.⁷ Lee, J.J.⁸

20
- 34548183776
- Neurotoxicity of bortezomib therapy in multiple myeloma: A single-center experience and review of the literature
- 17654660 10.1002/cncr.22921 1:CAS:528:DC%2BD2sXhtVChs7fP
- A Badros O Goloubeva JS Dalal I Can J Thompson AP Rapoport M Heyman G Akpek RG Fenton 2007 Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature Cancer 110 1042 1049 17654660 10.1002/cncr.22921 1:CAS:528:DC%2BD2sXhtVChs7fP
- (2007) Cancer , vol.110 , pp. 1042-1049
- Badros, A.¹ Goloubeva, O.² Dalal, J.S.³ Can, I.⁴ Thompson, J.⁵ Rapoport, A.P.⁶ Heyman, M.⁷ Akpek, G.⁸ Fenton, R.G.⁹

21
- 58449087374
- Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy
- 19192067 10.1111/j.1529-8027.2008.00193.x 1:CAS:528:DC%2BD1MXitF2gs7w%3D
- V Chaudhry DR Cornblath M Polydefkis A Ferguson I Borrello 2008 Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy J Peripher Nerv Syst 13 275 282 19192067 10.1111/j.1529-8027.2008.00193.x 1:CAS:528:DC%2BD1MXitF2gs7w%3D
- (2008) J Peripher Nerv Syst , vol.13 , pp. 275-282
- Chaudhry, V.¹ Cornblath, D.R.² Polydefkis, M.³ Ferguson, A.⁴ Borrello, I.⁵

22
- 84355161833
- Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma
- 21437586 10.1007/s00277-011-1217-0 1:CAS:528:DC%2BC3MXhsVGgu77F
- M Offidani L Corvatta C Polloni S Gentili A Mele R Rizzi M Catarini P Caraffa A Samori N Blasi M Ferranti L Malerba M Brunori P Leoni 2011 Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma Ann Hematol 90 1449 1456 21437586 10.1007/s00277-011-1217-0 1:CAS:528:DC%2BC3MXhsVGgu77F
- (2011) Ann Hematol , vol.90 , pp. 1449-1456
- Offidani, M.¹ Corvatta, L.² Polloni, C.³ Gentili, S.⁴ Mele, A.⁵ Rizzi, R.⁶ Catarini, M.⁷ Caraffa, P.⁸ Samori, A.⁹ Blasi, N.¹⁰ Ferranti, M.¹¹ Malerba, L.¹² Brunori, M.¹³ Leoni, P.¹⁴

23
- 79955977910
- Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
- 21292775 10.1182/blood-2010-10-299487 1:CAS:528:DC%2BC3MXmsVWnu7g%3D
- SV Rajkumar JL Harousseau B Durie KC Anderson M Dimopoulos R Kyle J Blade P Richardson R Orlowski D Siegel S Jagannath T Facon H Avet-Loiseau S Lonial A Palumbo J Zonder H Ludwig D Vesole O Sezer NC Munshi J San Miguel 2011 Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 Blood 117 4691 4695 21292775 10.1182/blood-2010-10-299487 1:CAS:528:DC%2BC3MXmsVWnu7g%3D
- (2011) Blood , vol.117 , pp. 4691-4695
- Rajkumar, S.V.¹ Harousseau, J.L.² Durie, B.³ Anderson, K.C.⁴ Dimopoulos, M.⁵ Kyle, R.⁶ Blade, J.⁷ Richardson, P.⁸ Orlowski, R.⁹ Siegel, D.¹⁰ Jagannath, S.¹¹ Facon, T.¹² Avet-Loiseau, H.¹³ Lonial, S.¹⁴ Palumbo, A.¹⁵ Zonder, J.¹⁶ Ludwig, H.¹⁷ Vesole, D.¹⁸ Sezer, O.¹⁹ Munshi, N.C.²⁰ San Miguel, J.²¹ more..

24
- 79952410108
- Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: A report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study
- 20947927 10.1093/jjco/hyq194
- SJ Kim K Kim YR Do SH Bae DH Yang JJ Lee 2011 Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study Jpn J Clin Oncol 41 353 357 20947927 10.1093/jjco/hyq194
- (2011) Jpn J Clin Oncol , vol.41 , pp. 353-357
- Kim, S.J.¹ Kim, K.² Do, Y.R.³ Bae, S.H.⁴ Yang, D.H.⁵ Lee, J.J.⁶

25
- 84988241358
- International uniform response criteria for multiple myeloma
- 16855634 10.1038/sj.leu.2404284 1:STN:280:DC%2BD28rgt1aqtA%3D%3D
- BG Durie JL Harousseau JS Miguel J Blade B Barlogie K Anderson M Gertz M Dimopoulos J Westin P Sonneveld H Ludwig G Gahrton M Beksac J Crowley A Belch M Boccadaro M Cavo I Turesson D Joshua D Vesole R Kyle R Alexanian G Tricot M Attal G Merlini R Powles P Richardson K Shimizu P Tosi G Morgan SV Rajkumar 2006 International uniform response criteria for multiple myeloma Leukemia 20 1467 1473 16855634 10.1038/sj.leu.2404284 1:STN:280:DC%2BD28rgt1aqtA%3D%3D
- (2006) Leukemia , vol.20 , pp. 1467-1473
- Durie, B.G.¹ Harousseau, J.L.² Miguel, J.S.³ Blade, J.⁴ Barlogie, B.⁵ Anderson, K.⁶ Gertz, M.⁷ Dimopoulos, M.⁸ Westin, J.⁹ Sonneveld, P.¹⁰ Ludwig, H.¹¹ Gahrton, G.¹² Beksac, M.¹³ Crowley, J.¹⁴ Belch, A.¹⁵ Boccadaro, M.¹⁶ Cavo, M.¹⁷ Turesson, I.¹⁸ Joshua, D.¹⁹ Vesole, D.²⁰ more..

26
- 74049142026
- The use of novel agents in the treatment of relapsed and refractory multiple myeloma
- 19741729 10.1038/leu.2009.179 1:CAS:528:DC%2BD1MXhsFKns7bK
- JP Laubach A Mahindra CS Mitsiades RL Schlossman NC Munshi IM Ghobrial N Carreau T Hideshima KC Anderson PG Richardson 2009 The use of novel agents in the treatment of relapsed and refractory multiple myeloma Leukemia 23 2222 2232 19741729 10.1038/leu.2009.179 1:CAS:528:DC%2BD1MXhsFKns7bK
- (2009) Leukemia , vol.23 , pp. 2222-2232
- Laubach, J.P.¹ Mahindra, A.² Mitsiades, C.S.³ Schlossman, R.L.⁴ Munshi, N.C.⁵ Ghobrial, I.M.⁶ Carreau, N.⁷ Hideshima, T.⁸ Anderson, K.C.⁹ Richardson, P.G.¹⁰

27
- 0034985413
- Immunomodulating anticancer alkylating drugs: Targets and mechanisms of activity
- 11469719 10.2174/1389450013348597 1:CAS:528:DC%2BD3MXktlSqsbs%3D
- S Ben-Efraim 2001 Immunomodulating anticancer alkylating drugs: targets and mechanisms of activity Curr Drug Targets 2 197 212 11469719 10.2174/1389450013348597 1:CAS:528:DC%2BD3MXktlSqsbs%3D
- (2001) Curr Drug Targets , vol.2 , pp. 197-212
- Ben-Efraim, S.¹

28
- 0035674305
- Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model
- 11807622 10.1007/s00262-001-0237-3 1:CAS:528:DC%2BD38XhsVens7w%3D
- P Matar VR Rozados SI Gervasoni GO Scharovsky 2002 Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model Cancer Immunol Immunother 50 588 596 11807622 10.1007/s00262-001-0237-3 1:CAS:528:DC%2BD38XhsVens7w%3D
- (2002) Cancer Immunol Immunother , vol.50 , pp. 588-596
- Matar, P.¹ Rozados, V.R.² Gervasoni, S.I.³ Scharovsky, G.O.⁴

29
- 33744489589
- A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma
- 16757429 10.1532/IJH97.A30512 1:CAS:528:DC%2BD28XmtFOrurs%3D
- SM Bang JH Lee SS Yoon S Park CK Min CC Kim C Suh SK Sohn YH Min JJ Lee K Kim CM Seong HJ Yoon KS Cho DY Jo KH Lee NR Lee CS Kim 2006 A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma Int J Hematol 83 309 313 16757429 10.1532/IJH97.A30512 1:CAS:528:DC%2BD28XmtFOrurs%3D
- (2006) Int J Hematol , vol.83 , pp. 309-313
- Bang, S.M.¹ Lee, J.H.² Yoon, S.S.³ Park, S.⁴ Min, C.K.⁵ Kim, C.C.⁶ Suh, C.⁷ Sohn, S.K.⁸ Min, Y.H.⁹ Lee, J.J.¹⁰ Kim, K.¹¹ Seong, C.M.¹² Yoon, H.J.¹³ Cho, K.S.¹⁴ Jo, D.Y.¹⁵ Lee, K.H.¹⁶ Lee, N.R.¹⁷ Kim, C.S.¹⁸

30
- 33749051832
- Development of neuropathy in patients with myeloma treated with thalidomide: Patterns of occurrence and the role of electrophysiologic monitoring
- 16940275 10.1200/JCO.2006.05.6689 1:CAS:528:DC%2BD28XhtVyisrrF
- L Mileshkin R Stark B Day JF Seymour JB Zeldis HM Prince 2006 Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring J Clin Oncol 24 4507 4514 16940275 10.1200/JCO.2006.05.6689 1:CAS:528:DC%2BD28XhtVyisrrF
- (2006) J Clin Oncol , vol.24 , pp. 4507-4514
- Mileshkin, L.¹ Stark, R.² Day, B.³ Seymour, J.F.⁴ Zeldis, J.B.⁵ Prince, H.M.⁶

31
- 77954304370
- Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: A retrospective study
- 20564642 10.1002/cncr.25143 1:CAS:528:DC%2BC3cXptlWqurY%3D
- JL Kaufman A Nooka M Vrana C Gleason LT Heffner S Lonial 2010 Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study Cancer 116 3143 3151 20564642 10.1002/cncr.25143 1:CAS:528:DC%2BC3cXptlWqurY%3D
- (2010) Cancer , vol.116 , pp. 3143-3151
- Kaufman, J.L.¹ Nooka, A.² Vrana, M.³ Gleason, C.⁴ Heffner, L.T.⁵ Lonial, S.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.